AKTS

Aktis Oncology, Inc. operates as a clinical-stage biopharmaceutical company developing targeted radiotherapies for cancer treatment. Headquartered in Cambridge, Massachusetts, the company focuses on creating precisely targeted radioligand therapies that deliver radiation directly to cancer cells while minimizing damage to healthy tissue. Aktis's lead product candidate, AKTC-4007, is a radioligand therapy targeting patients with metastatic castration-resistant prostate cancer (mCRPC), currently in clinical development. The company's proprietary platform combines tumor-targeting molecules with radioactive isotopes to create therapies designed for cancers with high unmet medical needs. The company emerged from stealth mode in 2022 and completed its initial public offering in May 2024, raising approximately $150 million at a valuation that positioned it among emerging players in the radiopharmaceutical sector. Aktis has established strategic partnerships and collaborations to advance its pipeline and manufacturing capabilities for targeted radiotherapies. The company's approach addresses a growing market segment as radioligand therapies gain regulatory approvals and clinical acceptance in oncology. As of 2024, Aktis remains pre-revenue and focuses its resources on advancing clinical trials and expanding its pipeline of radioligand therapy candidates across multiple cancer indications. The company competes in the increasingly competitive radiopharmaceutical space alongside both established pharmaceutical companies and specialized biotechnology firms developing similar targeted radiation approaches.